These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 23023767)

  • 1. On the choice of doses for phase III clinical trials.
    Lisovskaja V; Burman CF
    Stat Med; 2013 May; 32(10):1661-76. PubMed ID: 23023767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose selection in seamless phase II/III clinical trials based on efficacy and safety.
    Kimani PK; Stallard N; Hutton JL
    Stat Med; 2009 Mar; 28(6):917-36. PubMed ID: 19152231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practical guidelines for adaptive seamless phase II/III clinical trials that use Bayesian methods.
    Kimani PK; Glimm E; Maurer W; Hutton JL; Stallard N
    Stat Med; 2012 Aug; 31(19):2068-85. PubMed ID: 22437262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of predictive probabilities in phase II and phase III clinical trials.
    Johns D; Andersen JS
    J Biopharm Stat; 1999 Mar; 9(1):67-79. PubMed ID: 10091910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Designing a series of decision-theoretic phase II trials in a small population.
    Hee SW; Stallard N
    Stat Med; 2012 Dec; 31(30):4337-51. PubMed ID: 22927289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation.
    Nixon RM; O'Hagan A; Oakley J; Madan J; Stevens JW; Bansback N; Brennan A
    Pharm Stat; 2009; 8(4):371-89. PubMed ID: 19340851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal choice of the number of treatments to be included in a clinical trial.
    Stallard N; Posch M; Friede T; Koenig F; Brannath W
    Stat Med; 2009 Apr; 28(9):1321-38. PubMed ID: 19243083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Some thoughts on sample size: a Bayesian-frequentist hybrid approach.
    Gordon Lan KK; Wittes JT
    Clin Trials; 2012 Oct; 9(5):561-9. PubMed ID: 22865839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting population entering phase III trials: a new stratified adaptive phase II design.
    Tournoux-Facon C; De Rycke Y; Tubert-Bitter P
    Stat Med; 2011 Apr; 30(8):801-11. PubMed ID: 21432875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A seamless phase II/III design with sample-size re-estimation.
    Bischoff W; Miller F
    J Biopharm Stat; 2009 Jul; 19(4):595-609. PubMed ID: 20183428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conservative sample size estimation in nonparametrics.
    De Martini D
    J Biopharm Stat; 2011 Jan; 21(1):24-41. PubMed ID: 21191852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.
    Schmidli H; Bretz F; Racine-Poon A
    Stat Med; 2007 Nov; 26(27):4925-38. PubMed ID: 17590875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A mathematical model for maximizing the value of phase 3 drug development portfolios incorporating budget constraints and risk.
    Patel NR; Ankolekar S; Antonijevic Z; Rajicic N
    Stat Med; 2013 May; 32(10):1763-77. PubMed ID: 23300097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous toxicity monitoring in phase II trials in oncology.
    Ivanova A; Qaqish BF; Schell MJ
    Biometrics; 2005 Jun; 61(2):540-5. PubMed ID: 16011702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decision making from Phase II to Phase III and the probability of success: reassured by "assurance"?
    Carroll KJ
    J Biopharm Stat; 2013; 23(5):1188-200. PubMed ID: 23957523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bayesian sample size determination in non-sequential clinical trials: Statistical aspects and some regulatory considerations.
    Grouin JM; Coste M; Bunouf P; Lecoutre B
    Stat Med; 2007 Nov; 26(27):4914-24. PubMed ID: 17559054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An alternative phase II/III design for continuous endpoints.
    Huang WS; Liu JP; Hsiao CF
    Pharm Stat; 2011; 10(2):105-14. PubMed ID: 20186724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A behavioural Bayes approach to the determination of sample size for clinical trials considering efficacy and safety: imbalanced sample size in treatment groups.
    Kikuchi T; Gittins J
    Stat Methods Med Res; 2011 Aug; 20(4):389-400. PubMed ID: 20223784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting the outcome of phase III trials using phase II data: a case study of clinical trial simulation in late stage drug development.
    De Ridder F
    Basic Clin Pharmacol Toxicol; 2005 Mar; 96(3):235-41. PubMed ID: 15733220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing the data combination rule for seamless phase II/III clinical trials.
    Hampson LV; Jennison C
    Stat Med; 2015 Jan; 34(1):39-58. PubMed ID: 25315892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.